JAMA Study Links Abortion Bans to 2.8% Rise in Expectant Miscarriage Care
Updated
Updated · Salon · May 26
JAMA Study Links Abortion Bans to 2.8% Rise in Expectant Miscarriage Care
3 articles · Updated · Salon · May 26
More than 123,000 miscarriages analyzed from 2018 to 2024 showed abortion-ban states had a 2.8% increase in expectant management and a 2.2% drop in medication treatment.
Among patients who still received drugs, ban states saw a 13.8% increase in misoprostol-only regimens rather than the mifepristone-misoprostol combination, a shift researchers tied to legal uncertainty and access restrictions.
Texas' post-Dobbs trigger ban made abortion a felony punishable by up to life in prison, and doctors' fear of violating unclear exceptions has been cited as delaying care for miscarriages and ectopic pregnancies.
Researchers and OB-GYNs said the study adds to evidence that abortion restrictions are reshaping obstetric care beyond elective abortion, potentially increasing infection, hemorrhage and other complications when patients lose treatment options.
Has new Texas medical guidance actually reduced patient harm in emergency pregnancy care?
When a doctor’s medical duty conflicts with the law, what happens to patient safety?
The Ripple Effects of U.S. Abortion Bans: Declining Miscarriage Care, Worsening Health Disparities, and Provider Shortages
Overview
Abortion bans in the United States have led to a decline in the quality and accessibility of miscarriage care. These bans have changed standard medical practices, making outcomes for patients less effective and riskier. A key reason is the limited availability of mifepristone, caused by legal challenges and institutional restrictions. As a result, healthcare providers are hesitant to use this medication for miscarriage treatment due to fear of criminal liability. This leads to patients experiencing delays or being denied necessary care, forcing them to endure more discomfort and increased health risks.